244 related articles for article (PubMed ID: 36705879)
1. The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy.
Hines JB; Kacew AJ; Sweis RF
Curr Oncol Rep; 2023 Mar; 25(3):189-199. PubMed ID: 36705879
[TBL] [Abstract][Full Text] [Related]
2. Targeting STING for cancer immunotherapy: From mechanisms to translation.
Huang R; Ning Q; Zhao J; Zhao X; Zeng L; Yi Y; Tang S
Int Immunopharmacol; 2022 Dec; 113(Pt A):109304. PubMed ID: 36252492
[TBL] [Abstract][Full Text] [Related]
3. A 2D Nanoradiosensitizer Enhances Radiotherapy and Delivers STING Agonists to Potentiate Cancer Immunotherapy.
Luo T; Nash GT; Jiang X; Feng X; Mao J; Liu J; Juloori A; Pearson AT; Lin W
Adv Mater; 2022 Sep; 34(39):e2110588. PubMed ID: 35952624
[TBL] [Abstract][Full Text] [Related]
4. Chemical Biology Perspectives on STING Agonists as Tumor Immunotherapy.
Xuan C; Hu R
ChemMedChem; 2023 Dec; 18(23):e202300405. PubMed ID: 37794702
[TBL] [Abstract][Full Text] [Related]
5. STING pathway as a cancer immunotherapy: Progress and challenges in activating anti-tumor immunity.
Tabar MMM; Fathi M; Kazemi F; Bazregari G; Ghasemian A
Mol Biol Rep; 2024 Apr; 51(1):487. PubMed ID: 38578532
[TBL] [Abstract][Full Text] [Related]
6. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
7. Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy.
Luo K; Li N; Ye W; Gao H; Luo X; Cheng B
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889509
[TBL] [Abstract][Full Text] [Related]
8. Insight into the dichotomous regulation of STING activation in immunotherapy.
Hu Z; Yang Y; Fang L; Zhou J; Zhang H
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):126-137. PubMed ID: 33618600
[TBL] [Abstract][Full Text] [Related]
9. Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.
Corrales L; Gajewski TF
Clin Cancer Res; 2015 Nov; 21(21):4774-9. PubMed ID: 26373573
[TBL] [Abstract][Full Text] [Related]
10. Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies.
Zhang J; Yu S; Peng Q; Wang P; Fang L
Cancer Biol Med; 2024 Jan; 21(1):45-64. PubMed ID: 38172538
[TBL] [Abstract][Full Text] [Related]
11. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
[TBL] [Abstract][Full Text] [Related]
12. Unlocking the promise of systemic STING agonist for cancer immunotherapy.
Sun X; Zhou X; Lei YL; Moon JJ
J Control Release; 2023 May; 357():417-421. PubMed ID: 37001564
[TBL] [Abstract][Full Text] [Related]
13. DNA Damage and Cancer Immunotherapy: A STING in the Tale.
Reisländer T; Groelly FJ; Tarsounas M
Mol Cell; 2020 Oct; 80(1):21-28. PubMed ID: 32810436
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicines targeting activation of STING to reshape tumor immune microenvironment and enhance immunotherapeutic efficacy.
Chen S; Peng A; Chen M; Zhan M
Front Oncol; 2022; 12():1093240. PubMed ID: 36741735
[TBL] [Abstract][Full Text] [Related]
15. Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Motedayen Aval L; Pease JE; Sharma R; Pinato DJ
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081170
[TBL] [Abstract][Full Text] [Related]
16. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy.
Li A; Yi M; Qin S; Song Y; Chu Q; Wu K
J Hematol Oncol; 2019 Apr; 12(1):35. PubMed ID: 30935414
[TBL] [Abstract][Full Text] [Related]
17. STING activation in cancer immunotherapy.
Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
[TBL] [Abstract][Full Text] [Related]
18. Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
Garland KM; Sheehy TL; Wilson JT
Chem Rev; 2022 Mar; 122(6):5977-6039. PubMed ID: 35107989
[TBL] [Abstract][Full Text] [Related]
19. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
[TBL] [Abstract][Full Text] [Related]
20. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]